LNCARSR and metastatic neoplasm: For instance, the LncRNAs MAYA, MALAT1 and LncARSR, have each been targeted for in vivo silencing using ASOs to ameliorate the burden of metastatic disease in mouse models (28), miR-34a mimic packaged in a liposomal nanoparticle, called MRX34, has gone through a phase I clinical trial in patients with advanced solid tumor (29).